{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T18:05:23Z","timestamp":1787162723883,"version":"build-2736575974"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,1,20]],"date-time":"2020-01-20T00:00:00Z","timestamp":1579478400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2020,1,20]],"date-time":"2020-01-20T00:00:00Z","timestamp":1579478400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000133","name":"Agency for Healthcare Research and Quality","doi-asserted-by":"publisher","award":["1 R03 HS025787-01"],"award-info":[{"award-number":["1 R03 HS025787-01"]}],"id":[{"id":"10.13039\/100000133","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Anesthesiol"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>The cost-benefit of stocking dantrolene in maternity units for treating malignant hyperthermia (MH) has been recently questioned because of the low incidence of MH crisis in the general population and the low utilization of general anesthesia in obstetrics. However, no study has examined the prevalence of MH susceptibility in obstetrics. This study aimed to assess the prevalence of MH diagnosis and associated factors in obstetric patients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      Data for this study came from the National Inpatient Sample from 2003 to 2014, a 20% nationally representative sample of discharge records from community hospitals. A diagnosis of MH due to anesthesia was identified using the\n                      <jats:italic>International Classification of Diseases, Ninth Revision, Clinical Modification<\/jats:italic>\n                      code 995.86. MH prevalence was estimated according to the delivery mode and patient and hospital characteristics.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      During the 12-year study period, 47,178,322 delivery-related discharges [including 15,175,127 (32.2%) cesarean deliveries] were identified. Of them, 215 recorded a diagnosis of MH, yielding a prevalence of 0.46 per 100,000 [95% confidence interval (CI), 0.40 to 0.52]. The prevalence of MH diagnosis in cesarean deliveries was 0.81 per 100,000 (95% CI, 0.67 to 0.97), compared with 0.29 per 100,000 (95% CI, 0.23 to 0.35) in vaginal deliveries (\n                      <jats:italic>P<\/jats:italic>\n                      \u00a0&lt;\u2009\u00a00.001). Multivariable logistic regression revealed that cesarean delivery was associated with a significantly increased risk of MH diagnosis [adjusted rate ratio (aOR) 2.88; 95% CI, 2.19 to 3.80]. Prevalence of MH diagnosis was lower in Hispanics than in non-Hispanic whites (aOR 0.47; 95% CI, 0.29 to 0.76) and higher in the South than in the Northeast census regions (aOR 2.44; 95% CI, 1.50 to 3.96).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>The prevalence of MH-susceptibility is about 1 in 125,000 in cesarean deliveries, similar to the prevalence reported in non-obstetrical surgery inpatients. The findings of this study suggest that stocking dantrolene in maternity units is justified.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12871-020-0934-0","type":"journal-article","created":{"date-parts":[[2020,1,20]],"date-time":"2020-01-20T10:02:43Z","timestamp":1579514563000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Prevalence of malignant hyperthermia diagnosis in obstetric patients in the United States, 2003 to 2014"],"prefix":"10.1186","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8699-0724","authenticated-orcid":false,"given":"Jean","family":"Guglielminotti","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henry","family":"Rosenberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guohua","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,1,20]]},"reference":[{"key":"934_CR1","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1097\/ALN.0000000000001877","volume":"128","author":"RS Litman","year":"2018","unstructured":"Litman RS, Griggs SM, Dowling JJ, Riazi S. Malignant hyperthermia susceptibility and related diseases. Anesthesiology. 2018;128:159\u201367.","journal-title":"Anesthesiology"},{"key":"934_CR2","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1186\/s13023-015-0310-1","volume":"10","author":"H Rosenberg","year":"2015","unstructured":"Rosenberg H, Pollock N, Schiemann A, Bulger T, Stowell K. Malignant hyperthermia: a review. Orphanet J Rare Dis. 2015;10:93.","journal-title":"Orphanet J Rare Dis"},{"key":"934_CR3","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1097\/ALN.0000000000002490","volume":"130","author":"MG Larach","year":"2019","unstructured":"Larach MG, Klumpner TT, Brandom BW, Vaughn MT, Belani KG, Herlich A, et al. Succinylcholine use and dantrolene availability for malignant hyperthermia treatment: database analyses and systematic review. Anesthesiology. 2019;130:41\u201354.","journal-title":"Anesthesiology"},{"key":"934_CR4","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1213\/ANE.0b013e3182937d8b","volume":"118","author":"S Riazi","year":"2014","unstructured":"Riazi S, Larach MG, Hu C, Wijeysundera D, Massey C, Kraeva N. Malignant hyperthermia in Canada: characteristics of index anesthetics in 129 malignant hyperthermia susceptible probands. Anesth Analg. 2014;118:381\u20137.","journal-title":"Anesth Analg"},{"key":"934_CR5","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1097\/ALN.0000000000001878","volume":"128","author":"S Riazi","year":"2018","unstructured":"Riazi S, Kraeva N, Hopkins PM. Malignant hyperthermia in the post-genomics era: new perspectives on an old concept. Anesthesiology. 2018;128:168\u201380.","journal-title":"Anesthesiology."},{"key":"934_CR6","doi-asserted-by":"publisher","first-page":"1359","DOI":"10.1213\/ANE.0000000000000421","volume":"119","author":"MG Larach","year":"2014","unstructured":"Larach MG, Brandom BW, Allen GC, Gronert GA, Lehman EB. Malignant hyperthermia deaths related to inadequate temperature monitoring, 2007-2012: a report from the north American malignant hyperthermia registry of the malignant hyperthermia association of the United States. Anesth Analg. 2014;119:1359\u201366.","journal-title":"Anesth Analg"},{"key":"934_CR7","doi-asserted-by":"publisher","first-page":"1235","DOI":"10.1213\/ANE.0000000000000487","volume":"119","author":"SL Shafer","year":"2014","unstructured":"Shafer SL, Dexter F, Brull SJ. Deadly heat: economics of continuous temperature monitoring during general anesthesia. Anesth Analg. 2014;119:1235\u20137.","journal-title":"Anesth Analg"},{"key":"934_CR8","doi-asserted-by":"publisher","first-page":"1162","DOI":"10.1213\/ane.0b013e3181ac1548","volume":"109","author":"JE Brady","year":"2009","unstructured":"Brady JE, Sun LS, Rosenberg H, Li G. Prevalence of malignant hyperthermia due to anesthesia in New York state, 2001-2005. Anesth Analg. 2009;109:1162\u20136.","journal-title":"Anesth Analg"},{"key":"934_CR9","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1213\/ANE.0000000000001054","volume":"122","author":"Z Lu","year":"2016","unstructured":"Lu Z, Rosenberg H, Brady JE, Li G. Prevalence of malignant hyperthermia diagnosis in New York state ambulatory surgery center discharge records 2002 to 2011. Anesth Analg. 2016;122:449\u201353.","journal-title":"Anesth Analg"},{"key":"934_CR10","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1097\/ALN.0000000000002231","volume":"129","author":"PT Ho","year":"2018","unstructured":"Ho PT, Carvalho B, Sun EC, Macario A, Riley ET. Cost-benefit analysis of maintaining a fully stocked malignant hyperthermia cart versus an initial dantrolene treatment dose for maternity units. Anesthesiology. 2018;129:249\u201359.","journal-title":"Anesthesiology"},{"key":"934_CR11","unstructured":"Malignant Hyperthermia Association of the United States. Frequently asked questions: Who should stock dantrolene ? Available at: https:\/\/www.mhaus.org\/faqs\/. Last accessed: November 7, 2018."},{"key":"934_CR12","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1097\/ALN.0000000000002279","volume":"129","author":"CA Wong","year":"2018","unstructured":"Wong CA. Dantrolene and malignant hyperthermia carts: do we need them on maternity units? Anesthesiology. 2018;129:225\u20137.","journal-title":"Anesthesiology"},{"key":"934_CR13","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1007\/s10995-007-0256-6","volume":"12","author":"EV Kuklina","year":"2008","unstructured":"Kuklina EV, Whiteman MK, Hillis SD, Jamieson DJ, Meikle SF, Posner SF, et al. An enhanced method for identifying obstetric deliveries: implications for estimating maternal morbidity. Matern Child Health J. 2008;12:469\u201377.","journal-title":"Matern Child Health J"},{"key":"934_CR14","doi-asserted-by":"publisher","first-page":"957","DOI":"10.1097\/AOG.0b013e3182a603bb","volume":"122","author":"BT Bateman","year":"2013","unstructured":"Bateman BT, Mhyre JM, Hernandez-Diaz S, Huybrechts KF, Fischer MA, Creanga AA, et al. Development of a comorbidity index for use in obstetric patients. Obstet Gynecol. 2013;122:957\u201365.","journal-title":"Obstet Gynecol"},{"key":"934_CR15","doi-asserted-by":"publisher","first-page":"1130","DOI":"10.1097\/01.mlr.0000182534.19832.83","volume":"43","author":"H Quan","year":"2005","unstructured":"Quan H, Sundararajan V, Halfon P, Fong A, Burnand B, Luthi JC, et al. Coding algorithms for defining comorbidities in ICD-9-CM and ICD-10 administrative data. Med Care. 2005;43:1130\u20139.","journal-title":"Med Care"},{"key":"934_CR16","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1093\/aje\/kwq433","volume":"173","author":"H Quan","year":"2011","unstructured":"Quan H, Li B, Couris CM, Fushimi K, Graham P, Hider P, et al. Updating and validating the Charlson comorbidity index and score for risk adjustment in hospital discharge abstracts using data from 6 countries. Am J Epidemiol. 2011;173:676\u201382.","journal-title":"Am J Epidemiol"},{"key":"934_CR17","unstructured":"Healthcare Cost and Utilization Project. Producing national HCUP estimates. Available at: https:\/\/www.hcup-us.ahrq.gov\/tech_assist\/nationalestimates\/508_course\/508course_2018.jsp. Last accessed: November 22, 2019."},{"key":"934_CR18","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1097\/ALN.0b013e318190bb08","volume":"110","author":"EB Rosero","year":"2009","unstructured":"Rosero EB, Adesanya AO, Timaran CH, Joshi GP. Trends and outcomes of malignant hyperthermia in the United States, 2000 to 2005. Anesthesiology. 2009;110:89\u201394.","journal-title":"Anesthesiology"},{"key":"934_CR19","doi-asserted-by":"publisher","first-page":"958","DOI":"10.1111\/j.1460-9592.2011.03649.x","volume":"21","author":"G Li","year":"2011","unstructured":"Li G, Brady JE, Rosenberg H, Sun LS. Excess comorbidities associated with malignant hyperthermia diagnosis in pediatric hospital discharge records. Paediatr Anaesth. 2011;21:958\u201363.","journal-title":"Paediatr Anaesth"},{"key":"934_CR20","doi-asserted-by":"publisher","first-page":"472","DOI":"10.1213\/ANE.0000000000000679","volume":"122","author":"AJ Butwick","year":"2016","unstructured":"Butwick AJ, Blumenfeld YJ, Brookfield KF, Nelson LM, Weiniger CF. Racial and ethnic disparities in mode of anesthesia for cesarean delivery. Anesth Analg. 2016;122:472\u20139.","journal-title":"Anesth Analg"},{"key":"934_CR21","doi-asserted-by":"publisher","first-page":"912","DOI":"10.1097\/ALN.0000000000002629","volume":"130","author":"J Guglielminotti","year":"2019","unstructured":"Guglielminotti J, Landau R, Li G. Adverse events and factors associated with potentially avoidable use of general anesthesia in cesarean deliveries. Anesthesiology. 2019;130:912\u201322.","journal-title":"Anesthesiology"},{"key":"934_CR22","doi-asserted-by":"publisher","first-page":"696","DOI":"10.1007\/BF03013380","volume":"44","author":"M Bachand","year":"1997","unstructured":"Bachand M, Vachon N, Boisvert M, Mayer FM, Chartrand D. Clinical reassessment of malignant hyperthermia in Abitibi-Temiscamingue. Can J Anaesth. 1997;44:696\u2013701.","journal-title":"Can J Anaesth"},{"key":"934_CR23","doi-asserted-by":"publisher","first-page":"1333","DOI":"10.1097\/ALN.0000000000000257","volume":"120","author":"T Aderibigbe","year":"2014","unstructured":"Aderibigbe T, Lang BH, Rosenberg H, Chen Q, Li G. Cost-effectiveness analysis of stocking dantrolene in ambulatory surgery centers for the treatment of malignant hyperthermia. Anesthesiology. 2014;120:1333\u20138.","journal-title":"Anesthesiology"},{"key":"934_CR24","doi-asserted-by":"publisher","first-page":"973","DOI":"10.1097\/AOG.0000000000000219","volume":"123","author":"ME D'Alton","year":"2014","unstructured":"D'Alton ME, Main EK, Menard MK, Levy BS. The National Partnership for maternal safety. Obstet Gynecol. 2014;123:973\u20137.","journal-title":"Obstet Gynecol"},{"key":"934_CR25","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1097\/ALN.0000000000000467","volume":"122","author":"T Pinyavat","year":"2015","unstructured":"Pinyavat T, Rosenberg H, Lang BH, Wong CA, Riazi S, Brady JE, et al. Accuracy of malignant hyperthermia diagnoses in hospital discharge records. Anesthesiology. 2015;122:55\u201363.","journal-title":"Anesthesiology"},{"key":"934_CR26","doi-asserted-by":"publisher","first-page":"e1001885","DOI":"10.1371\/journal.pmed.1001885","volume":"12","author":"EI Benchimol","year":"2015","unstructured":"Benchimol EI, Smeeth L, Guttmann A, Harron K, Moher D, Petersen I, et al. The REporting of studies conducted using observational routinely-collected health data (RECORD) statement. PLoS Med. 2015;12:e1001885.","journal-title":"PLoS Med"},{"key":"934_CR27","doi-asserted-by":"publisher","first-page":"1453","DOI":"10.1016\/S0140-6736(07)61602-X","volume":"370","author":"E von Elm","year":"2007","unstructured":"von Elm E, Altman DG, Egger M, Pocock SJ, Gotzsche PC, Vandenbroucke JP. The strengthening the reporting of observational studies in epidemiology (STROBE) statement: guidelines for reporting observational studies. Lancet. 2007;370:1453\u20137.","journal-title":"Lancet"}],"container-title":["BMC Anesthesiology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12871-020-0934-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12871-020-0934-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12871-020-0934-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,1,18]],"date-time":"2021-01-18T19:05:54Z","timestamp":1610996754000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcanesthesiol.biomedcentral.com\/articles\/10.1186\/s12871-020-0934-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,1,20]]},"references-count":27,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["934"],"URL":"https:\/\/doi.org\/10.1186\/s12871-020-0934-0","relation":{},"ISSN":["1471-2253"],"issn-type":[{"value":"1471-2253","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,1,20]]},"assertion":[{"value":"12 February 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 January 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 January 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The study protocol was granted exemption under 45 Code of Federal Regulation 46 (not human subjects research) by the Institutional Review Board of Columbia University Medical Center. The Strengthening The Reporting of OBservational studies in Epidemiology (STROBE) and the Reporting of studies Conducted using Observational Routinely-collected health Data (RECORD) statements were followed [\n                      \n                      ,\n                      \n                      ].. Administrative permission to access the data was granted by the Healthcare Cost and Utilization Project (HCUP).","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Dr. Henry Rosenberg is the president of the Malignant Hyperthermia Association of the United States. The content is solely the responsibility of this author and does not necessarily represent the official views of the Malignant Hyperthermia Association of the United States. The remaining authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"19"}}